Apolipoprotein E mimetic peptide, CN‐105, improves outcomes in ischemic stroke
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Objective: At present, the absence of a pharmacological neuroprotectant represents an important unmet clinical need in the treatment of ischemic and traumatic brain injury. Recent evidence suggests that administration of apolipoprotein E mimetic therapies represent a viable therapeutic strategy in this setting. We investigate the neuroprotective and anti‐inflammatory properties of the apolipoprotein E mimetic pentapeptide, CN‐105, in a microglial cell line and murine model of ischemic stroke. Methods: Ten to 13‐week‐old male C57/BL 6 mice underwent transient middle cerebral artery occlusion and were randomly selected to receive CN‐105 (0.1 mg/kg) in 100 μ L volume or vehicle via tail vein injection at various time points. Survival, motor‐sensory functional outcomes using rotarod test and 4‐limb wire hanging test, infarct volume assessment using 2,3,5‐Triphenyltetrazolium chloride staining method, and microglial activation in the contralateral hippocampus using F4/80 immunostaining were assessed at various time points. In vitro assessment of tumor necrosis factor‐alpha secretion in a microglial cell line was performed, and phosphoproteomic analysis conducted to explore early mechanistic pathways of CN‐105 in ischemic stroke. Results: Mice receiving CN‐105 demonstrated improved survival, improved functional outcomes, reduced infarct volume, and reduced microglial activation. CN‐105 also suppressed inflammatory cytokines secretion in microglial cells in vitro. Phosphoproteomic signals suggest that CN‐105 reduces proinflammatory pathways and lower oxidative stress. Interpretation: CN‐105 improves functional and histological outcomes in a murine model of ischemic stroke via modulation of neuroinflammatory pathways. Recent clinical trial of this compound has demonstrated favorable pharmacokinetic and safety profile, suggesting that CN‐105 represents an attractive candidate for clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells
Jin, R., Yang, G., & Li, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109766 · Cited by 1,521
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 3×
“More recently, it has been found that apoE stabilizes BBB through suppression of cyclophilin A (Peptidylprolyl cis-trans isomerase A or CypA) in an isoform-specific manner via interaction with LRP1.(57) We observed, through our phosphoproteomic study, that CN-105 downregulated phosphorylation of CypA in ischemic strok…”
BackgroundInfluentialApolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · cited 1×
“Isoform-specific protective effects on endogenous neuroinflammatory responses have been observed in humans across different acute brain injuries(25,26) but not in cerebral ischemia.(27,28) Due to its large size, apoE does not cross the blood–brain barrier (BBB) and its therapeutic potential is limited.”
BackgroundApolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., Warner, D. S., & Laskowitz, D. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306923200 · Cited by 394
Self-citationSchilling, M., Besselmann, M., Leonhard, C., Mueller, M., Ringelstein, E. B., & Kiefer, R. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00082-7 · Cited by 375
Cerebrovascular Effects of Apolipoprotein E: Implications for Alzheimer Disease
Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2152 · Cited by 263
Neuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside
Sutherland, B. A., Minnerup, J., Balami, J. S., Arba, F., Buchan, A. M., & Kleinschnitz, C. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2012.00770.x · Cited by 259 · cited 1×
“However, drugs targeting the inflammatory cascade have been unsuccessful in clinical trials, notably due to adverse effects and poor central nervous system (CNS) penetration.(13,14) Apolipoprotein E (apoE) is the primary apolipoprotein produced in the CNS, where its glial secretion is upregulated after injury.”
BackgroundApolipoprotein E and the CNS Response to Injury
Laskowitz, D. T., Horsburgh, K., & Roses, A. D. (1998) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199805000-00001 · Cited by 201
Self-citationApolipoprotein E suppresses glial cell secretion of TNFα
Laskowitz, D. T., Goel, S., Bennett, E. R., & Matthew, W. D. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00021-0 · Cited by 175
Self-citationApolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia
Laskowitz, D. T., Sheng, H., Bart, R. D., Joyner, K. A., Roses, A. D., & Warner, D. S. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199707000-00005 · Cited by 166
Self-citationApoE Deficiency Compromises the Blood Brain Barrier Especially After Injury
Methia, N., André, P., Hafezi-Moghadam, A., Economopoulos, M., Thomas, K. L., & Wagner, D. D. (2001) · Molecular Medicine · doi:10.1007/bf03401973 · Cited by 150
ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage
Hafezi-Moghadam, A., Thomas, K. L., & Wagner, D. D. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00563.2005 · Cited by 149
Lynch, J. R., Pineda, J. A., Morgan, D., Zhang, L., Warner, D. S., Benveniste, H., & Laskowitz, D. T. (2002) · Annals of Neurology · doi:10.1002/ana.10098 · Cited by 111
Self-citation
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“For example, peptides encompassing the apoE receptor binding region (amino acids 130–150) have been shown to reduce microglial immunoreactivity in vitro [196], and improve survival in mouse models of traumatic brain injury [197, 198] and AD [199].”
BackgroundExpression and secretion of apoE isoforms in astrocytes and microglia during inflammation
Lanfranco, M. F., Sepulveda, J., Kopetsky, G., & Rebeck, G. W. (2021) · Glia · doi:10.1002/glia.23974 · Cited by 164
ApoE mimetic improves pathology and memory in a model of Alzheimer’s disease
Krishnamurthy, K., Cantillana, V., Wang, H., Sullivan, P. M., Kolls, B. J., Ge, X., Lin, Y., Mace, B., & Laskowitz, D. T. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146685 · Cited by 39
Self-citation
Metadata
- Authors
- Tu, T. M., Kolls, B. J., Soderblom, E. J., Cantillana, V., Ferrell, P. D., Moseley, M. A., Wang, H., Dawson, H. N., & Laskowitz, D. T.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2017-03-09
- Volume
- 4
- Issue
- 4
- Pages
- 246-265
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2593726173
- Cited by
- 44
- References
- 15
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.